AstraZeneca PLC (AZN)vsCalciMedica, Inc. Common Stock (CALC)
AZN
AstraZeneca PLC
$188.41
+1.35%
HEALTHCARE · Cap: $284.30B
CALC
CalciMedica, Inc. Common Stock
$0.99
+24.62%
HEALTHCARE · Cap: $12.89M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CALC
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Intrinsic value data unavailable for CALC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : CALC
CALC has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while CALC is a value play — different risk/reward profiles.
CALC carries more volatility with a beta of 1.24 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 19/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that modulate calcium-dependent pathways to address acute and chronic health issues. Its lead candidate, CM4620, targets severe muscle cramps in patients with sickle cell disease, highlighting the company's commitment to tackling critical unmet medical needs. With a proprietary technology platform and a well-defined pipeline of novel calcium modulators, CalciMedica is well-positioned for growth. The company is supported by a seasoned management team and strategic partnerships aimed at accelerating its clinical development, making it a noteworthy investment opportunity in the biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?